Advanced ADC Solutions…Chemistry. Conjugation. Clinical Success.
At Cohance Lifesciences, we bring together the power of precision chemistry, bioconjugation expertise, and GMP manufacturing to accelerate Antibody-Drug Conjugate (ADC) development from discovery to clinic. Our integrated approach spans innovative payload and linker development, bioconjugation strategies, and clinical-grade manufacturing — all under one agile, compliant platform.
With NJ Bio as our strategic partner, we offer a CRDMO model purpose-built for ADCs — combining deep scientific insight with end-to-end execution. Whether it’s optimizing cytotoxic payloads or scaling conjugated molecules for clinical supply, Cohance Lifesciences is your trusted partner for success in the evolving ADC landscape.
Why Cohance for Small Molecule Manufacturing?
Why Partner with Cohance for ADCs?
- Integrated CRDMO model combining chemistry, biology, and manufacturing expertise
- Global pioneers in Camptothecin (CPT) derivatives & proprietary
S-Trione technology - High-containment facilities purpose-built for high-potency payloads and conjugates
- Robust backward integration ensuring supply chain control and delivery reliability
- Regulatory-ready platforms with DMFs and Phase-appropriate GMP infrastructure
- Strategic partnership with NJ Bio for discovery, bioconjugation, and clinical execution
Our Comprehensive ADC Capabilities
Payload & Linker
Development
• CPT & Auristatin derivative synthesis
• Proprietary s-Trione-based payloads
• Industry-standard & custom linkers
• Containment expertise for high-potency synthesis
Integrated
CRDMO Services
• Linker-payload optimization and bioconjugation
• Phase-appropriate GMP manufacturing
• Analytical development & regulatory documentation
• Discovery to IND support, tech transfer, and scale-up
Contact Us